ClinicalTrials.gg
CompletedNCT05244304DRAGONUpdated Jul 23, 2026

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease

A Phase 3 interventional study of Tinlarebant and Placebo in Stargardt Disease 1, sponsored by Belite Bio, Inc. Completed at 19 sites in 11 countries. Open to participants aged 12 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Belite Bio, Inc · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
12 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.

Enrollment
8th of 26
104 · median 41
Started
2022
with 1 other
Phase 3
3 of 42
1 open now
Registered
23rd of 42
by date
Lead sponsor
2 of 42
Belite Bio, Inc

Among the 42 studies in Stargardt Disease with a site in United States, this one is the 8th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2022, is one of 3 in phase 3, and was the 23rd registered.

Stargardt Disease

68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.

Browse Stargardt Disease studies →

Open to participants now

16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Stargardt Disease studies recruiting now, 15 (63%) set no upper age limit and 7 (29%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Stargardt Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1

Read the detailed description

Approximately 90 subjects will be enrolled in this study. Subjects will be assigned to study drug (tinlarebant 5 mg/placebo) with treatment period of upto 24 months with 28 days of follow-up.

03

Conditions studied

  • Stargardt Disease 1

Browse trials for

04

Who can participate

Ages eligible
12 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 12 to 20 years old, inclusive.
  • Subject must have clinically diagnosed STGD1 (Stargardt disease 1) with at least 1 mutation identified in the ABCA4 gene.
  • Subject must have a defined aggregate atrophic lesion size within 3 disc areas (7.62 mm2), as imaged by FAF in the study eye Subjects must have a BCVA of 20/200 or better for the study eye based on ETDRS letter score
  • Subject and their parent(s) or legal guardian are willing to provide their consent on an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)/Human Research Ethics Committee (HREC)-approved form (ICF) prior to participating in any study-related procedures.
  • Subject agrees to comply with all protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Any ocular disease other than Stargardt (STGD1) at baseline that, in the opinion of the investigator, would complicate assessment of a treatment effect.
  • History of ocular surgery in the study eye in the last 3 months.
  • drug use of any kind in the last 3 months or within 5 half-lives of the investigational drug, whichever is shorter.
  • Any prior gene therapy.
  • Vitamin A (retinol) deficiency as defined as a retinol serum level less than 20 mcg/dL (=0.7 μmol/L).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Tinlarebant

    5 mg tablet taken orally once a day

    Drug: Tinlarebant

  • Placebo comparator
    Placebo

    Placebo tablets for tinlarebant 5 mg are prepared similarly but use microcrystalline cellulose, NF, in place of the active drug substance and will be identical in size and appearance.

    Drug: Placebo

Interventions

  • Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.

  • DrugPlacebo

    Not active drug

06

What researchers measure

Primary outcomes

  1. To measure change in atrophic lesion size (definitely decreased autofluorescence, DDAF) by fundus autofluorescence (FAF) photography from baseline

    Time frame: Baseline thru month 24

Secondary outcomes

  1. To measure the change in retinal thickness assessed by spectral-domain optical coherence tomography (SD-OCT) from baseline

    Time frame: Baseline thru month 24

  2. To measure the change in retinal morphology assessed by spectral-domain optical coherence tomography (SD-OCT) from baseline

    Time frame: Baseline thru month 24

  3. To measure change in BCVA (Best Corrected Visual Acuity) score measured by the EDTRS method from baseline

    Time frame: Baseline thru month 24

  4. To measure change in plasma concentration of RBP4 levels (μM) from baseline

    Time frame: Baseline thru month 24

  5. The correlation between change in plasma RBP4 level and the rate of lesion size growth (definitely decreased autofluorescence, DDAF) by fundus autofluorescence (FAF) photography from baseline

    Time frame: Baseline thru month 24

  6. To assess the systemic and ocular safety and tolerability of tinlarebant

    Frequency, duration, and severity of AEs

    Time frame: Baseline thru month 24

Other outcomes

  1. To measure change in total decreased autofluorescence (DAF) by FAF photography from baseline

    Time frame: Baseline thru month 24

  2. To measure change in questionably decreased autofluorescence (QDAF) by FAF photography from baseline

    Time frame: Baseline thru month 24

  3. To measure change in quantitative autofluorescence (qAF) level from baseline

    Time frame: Baseline thru month 24

  4. To measure change in retinal sensitivity by microperimetry from baseline

    Time frame: Baseline thru month 24

07

Study locations

19 sites
  • Belite Study Site
    Palo Alto, California 94303, United States
  • Belite Study Site
    Minneapolis, Minnesota 55435, United States
  • Belite Study Site
    Salt Lake City, Utah 84132, United States
  • Belite Study Site
    Westmead, New South Wales, Australia
  • Belite Study Site
    East Melbourne, Victoria, Australia
  • Belite Study Site
    South Brisbane, Australia
  • Belite Study Site
    Ghent, Belgium
  • Belite Study Site
    Beijing, China
  • Belite Study Site
    Shanghai, China
  • Belite Study Site
    Paris, France
  • Belite Study Site
    Bonn, Germany
  • Belite Study Site
    Tübingen, Germany
  • Belite Study Site
    Kowloon, Hong Kong
  • Belite Study Site
    Nijmegen, Netherlands
  • Belite Study Site
    Basel, Switzerland
  • Belite Study Site
    Taipei, Taiwan
  • Belite Study Site
    Taoyuan City, Taiwan
  • Belite Study Site
    London, United Kingdom
  • Belite Study Site
    Southampton, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Aug 2025, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2022
First posted
Feb 17, 2022
StartActual
Mar 28, 2022
Primary completionActual
Aug 4, 2025
CompletionActual
Sep 11, 2025
Results delay requested
Jul 21, 2026
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05244304
Lead sponsor
Belite Bio, Inc
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Mar 28, 2022
Primary completion
Aug 4, 2025
Completion
Sep 11, 2025
Last update
Jul 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tinlarebant

Start the discussion